Initial experience using a bipolar radiofrequency ablation device for hemostasis during thyroidectomy.
The purpose of this study was to evaluate a novel bipolar radiofrequency ablation (BRFA) device using nanotechnology for division of all named vessels during thyroidectomy. All thyroidectomies from January 2008 to July 2010 at a single institution used the BRFA device (EnSeal, Ethicon Endo-Surgery, Cincinnati, OH) for hemostasis. Clinicopathologic data and complications were recorded and compared with existing literature using other energy devices. Fifty-eight thyroidectomies were performed. Mean age was 54.7 years, and mean operating room time was 81 minutes. The average estimated blood loss was 46 mL. Ninety percent of patients were discharged in <23 hours. There were no hemorrhages. There was 1 recurrent laryngeal nerve (RLN) injury, and 1 case of transient hypocalcemia. This first small series using the BRFA device reveals initial safety and effectiveness for thyroid hemostasis, and warrants further study. The minimal thermal spread inherent in this device may make it an attractive option when structures such as the RLN may be near the zone of hemostasis.